** HK-listed shares of Laekna 2105.HK soar 37.2% to HK$14.54, highest since Jan. 11
** Stock set for biggest one-day pct rise since April 15
** Chinese biotech firm enters into agreement with Eli Lilly LLY.N to accelerate global clinical development of LAE102, used to treat obesity
** Under the deal, Lilly will fund and execute LAE102's phase I study in the U.S., while Laekna will retain the drug's global rights
** Hong Kong's healthcare index .HSCIH up 2.8%, while Hang Seng Index .HSI slips 0.1%
** Stock trims YTD losses to 32.3%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。